These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Concentrations of nitric oxide metabolites in the serum of Iranian multiple sclerosis patients. Roghani M; Mahboudi F; Saharian MA; Etemadifar M; Esfahani AN; Nahrevanian H; Elahi E J Neurol Sci; 2010 Jul; 294(1-2):92-4. PubMed ID: 20434172 [TBL] [Abstract][Full Text] [Related]
10. Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation with disease activity. Drulović J; Dujmović I; Mesaros S; Samardzić T; Maksimović D; Stojsavljević N; Lević Z; Mostarica Stojokvić M Mult Scler; 2001 Feb; 7(1):19-22. PubMed ID: 11321188 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342 [TBL] [Abstract][Full Text] [Related]
12. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis. Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417 [TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623 [TBL] [Abstract][Full Text] [Related]